Patent intelligence · US
US 12043607
HDAC inhibitors and therapeutic use thereof
HDAC inhibitors and therapeutic use thereof
Patent details — US 12043607
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 23, 2024
- Expiration
- Jul 18, 2044
- Applicant
- Tango Therapeutics, Inc.
- Claims
- 34
- CPC classes
- A61P, A61P35/00
Quick answer
US 12043607 (HDAC inhibitors and therapeutic use thereof) is held by Tango Therapeutics, Inc.. Status: granted. Granted Jul 23, 2024. Expires Jul 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Tango Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 34
- CPC classes
- A61P, A61P35/00
More from Tango Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12403137
Compounds and methods of use
granted -
US 12304907
Compounds and methods of use
granted -
US 12264154
Compounds and methods of use
granted -
US 11999727
Compounds and methods of use
granted -
US 11986471
Compounds and methods of use
granted -
US 11492350
Compounds and methods of use
granted -
US 11077101
Compounds and methods of use
granted
Frequently asked questions
What is US patent 12043607?
US 12043607 (HDAC inhibitors and therapeutic use thereof) is held by Tango Therapeutics, Inc.. Status: granted. Granted Jul 23, 2024. Expires Jul 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12043607?
Tango Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 12043607 expire?
Our index shows an expiration date of Jul 18, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.